Abstract:Clinical studies have shown that insulin receptor (IR) and the insulin-like growth factor(IGF)-1-receptor (IGF-1R) signaling are largely reduced in the brains of patients suffering from Alzheimer's disease (AD) and other neurodegenerative diseases. Whether the impaired IR/IGF-1R signaling is cause, consequence or even counterregulation to neurodegeneration and whether the accompanying changes in IR/IGF-1R mediated transcription are involved in the pathogenesis of AD is currently a matter of debate. Recent studies have shown that IGF-1 resistance induces Ab hyperaggregation leading to Ab-detoxification and rescues the increased mortality of APP (amyloid precursor protein) overexpressing mice. Since FoxO transcription factors are highly likely candidates to mediate these effects, two mouse strains have been established, one expressing a constitutively active FoxO1 mutant (FoxO1ADA), the other a dominant negative mutant FoxO1 (FoxO1DN). To analyse the role of FoxO1 mediated transcription for AD pathology Tg2576 mice overexpressing the human derived mutant APP form (APPsw) with a size of 695 amino acids were used. This APP variant harbours an amino acid substitution of Lys670 to Asn and Met671 to Leu, so called “swedish mutation” (APPsw) leading to an increased generation of Aβ. Mice expressing neuronspecifically the dominant negative (FoxO1DN) or the constitutive active form of FoxO1 (FoxO1ADA) were crossed with Tg2576 mice. The different genotypes (wild-type, FoxO1DN, Tg2576/FoxO1DN, FoxO1ADA, Tg2576/FoxO1ADA and Tg2576 mice) were used to analyse glucose metabolism, insulin and IGF-1 signaling, survival (Kaplan-Meier) and APP processing up to 60 weeks of age. Mice in Tg2576 background displayed unaltered glucose homeostasis. Furthermore, Kaplan-Meier analysis revealed no differences in survival of Tg2576/FoxO1DN female and male mice compared to Tg2576 mice. Surprisingly, Tg2576/FoxO1ADA female mice showed an increase of premature death in comparison with Tg2576 female mice without reaching statistical significance. Interestingly Tg2576/FoxO1ADA male mice did not live longer than 16 weeks. Additionally, western blot analysis from brain lysates of the different genotypes did not reveal alteration of the IR/IGF- 1R signaling pathway. Processing of APP in Tg2576/FoxO1DN and Tg2576/FoxO1ADA mice was unchanged compared to Tg2576 mice. The level of a/bCTFs as well as Ab40 and Ab42 burden revealed no differences in the genotypes with AD background. Furthermore, accumulation of Ab oligomers was not influenced by FoxO1 mediated transcription. The results of the current study exclude FoxO1 mediated transcription as the underlying mechanism of the beneficial effects of IGF-1 resistance on AD pathology in Tg2576 mice.

Identification of IGF-1 Effects on White Adipose Tissue and Hippocampus in Alzheimer's Disease Mice via Transcriptomic and Cellular Analysis

The Effect of Chronic Cerebral Hypoperfusion on Amyloid-β Metabolism in a Transgenic Mouse Model of Alzheimer's Disease (PS1V97L).

Hypothalamic and hippocampal transcriptome changes in AppNL-G-F mice as a function of metabolic and inflammatory dysfunction

Multiple Inflammatory Profiles of Microglia and Altered Neuroimages in APP/PS1 Transgenic AD Mice.

iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer's Disease.

Proteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean red ginseng on Alzheimer's disease in a mouse model

Sex-specific hypothalamic neuropathology and glucose metabolism in an amyloidosis transgenic mouse model of Alzheimer's disease

Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology

Sex-specific Hypothalamic Neuropathology and Glucose Metabolism in an Amyloidosis Transgenic Mouse Model of Alzheimer’s Disease

The role of FoxO1 in neurodegenerative diseases

Identification of immunogenic cell death-related genes involved in Alzheimer's disease

Comparative Phosphoproteomics of Neuro-2a Cells under Insulin Resistance Reveals New Molecular Signatures of Alzheimer’s Disease

Hippocampus proteomics and brain lipidomics reveal network dysfunction and lipid molecular abnormalities in APP/PS1 mouse model of Alzheimer's disease.

Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-β Peptides and Insulin

Insulin-Like Growth Factor Signaling in Alzheimer's Disease: Pathophysiology and Therapeutic Strategies

Phosphoproteomic analysis of APP/PS1 mice of Alzheimer's disease by DIA based mass spectrometry analysis with PRM verification

Identification of biomarkers of Alzheimer's disease and their characterization of immune function

Characterization of the Chromatin Accessibility in an Alzheimer’s Disease (AD) Mouse Model

Identification of Key Transcriptome Biomarkers Based on a Vital Gene Module Associated with Pathological Changes in Alzheimer's Disease.

Spatiotemporal characterization of glial cell activation in an Alzheimer's disease model by spatially resolved transcriptomics